Keith D. Eaton
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Keith D. Eaton has a total of 37 co-authors. Here are the top co-authors by number of shared publications:
- Christina S. Baik
Fred Hutchinson Cancer Research Center, Seattle, WA
4 shared publications Bernardo H. L. Goulart
Seattle Cancer Care Alliance, Fred Hutchinson Cancer Research Center, Seattle, WA
3 shared publicationsCristina P. Rodriguez
Division of Medical Oncology, University of Washington, Seattle, WA
3 shared publicationsLaura Quan Man Chow
Division of Medical Oncology, University of Washington, Seattle, WA
3 shared publications- Rafael Santana-Davila
University of Washington, Seattle, WA
3 shared publications Renato G. Martins
Division of Medical Oncology, University of Washington, Seattle, WA
3 shared publications
Latest Publications
- Open Access
- 14 January 2019
- Published by Springer Nature in BMC Cancer
- Vol. 19 (1) , 70
Long term follow-up of neoadjuvant chemotherapy for non-small cell lung cancer (NSCLC) investigating early positron emission tomography (PET) scan as a predictor of outcome
Neoadjuvant chemotherapy is effective in improving survival of resectable NSCLC. Based on findings in the adjuvant and metastatic setting, FDG positron emission tomography (PET) scans may offer early prognostic or predictive value after one cycle of induction chemotherapy. In this phase II non-randomized trial, patients with AJCC version 6 stage IB to IIIB operable NSCLC were treated with 3 cycles of cisplatin and pemetrexed neoadjuvant chemotherapy. Patients underwent FDG-PET scanning prior to and 18 to 21 days after the first cycle of chemotherapy. Investigators caring for patients were blinded to results, unless the scans showed evidence of disease progression. FDG-PET response was defined prospectively as a ≥ 20% decrease in the SUV of the primary lesion. Between October 2005 and February 2010, 25 patients enrolled. Fifty two percent were female, 88% white, and median age was 62 years. Histology was divided into adenocarcinoma 66%, not otherwise specified (NOS) 16%, squamous cell 12%, and large cell 4%. Stage distribution was: 16% IB, 4% IIB, and 79% IIIA. Treatment was well tolerated and only one patient had a grade 4 toxicity. The median follow up was 95 months. The 5 year progression free survival (PFS) and overall survival (OS) for the entire population were 54 and 67%, respectively. Eighteen patients had a baseline FDG-PET scan and a repeat scan at day 18–21 available for comparison. Ten patients (56%) were considered metabolic responders on the day 18–21 FDG-PET scan. Responders had a 5 year PFS and OS of 60 and 70%, respectively, while the percentage for non-responders was 63 and 75% (p = 0.96 and 0.85). This phase II trial did not demonstrate that a PET scan after one cycle of chemotherapy can predict survival outcomes of patients with NSCLC treated with neoadjuvant chemotherapy. NCT00227539 registered September 28th, 2005.
- 14 January 2019
- Published by Springer Nature in BMC Cancer
- Vol. 19 (1) , 70
Open AccessLong term follow-up of neoadjuvant chemotherapy for non-small cell lung cancer (NSCLC) investigating early positron emission tomography (PET) scan as a predictor of outcome
Neoadjuvant chemotherapy is effective in improving survival of resectable NSCLC. Based on findings in the adjuvant and metastatic setting, FDG positron emission tomography (PET) scans may offer early prognostic or predictive value after one cycle of induction chemotherapy. In this phase II non-randomized trial, patients with AJCC version 6 stage IB to IIIB operable NSCLC were treated with 3 cycles of cisplatin and pemetrexed neoadjuvant chemotherapy. Patients underwent FDG-PET scanning prior to and 18 to 21 days after the first cycle of chemotherapy. Investigators caring for patients were blinded to results, unless the scans showed evidence of disease progression. FDG-PET response was defined prospectively as a ≥ 20% decrease in the SUV of the primary lesion. Between October 2005 and February 2010, 25 patients enrolled. Fifty two percent were female, 88% white, and median age was 62 years. Histology was divided into adenocarcinoma 66%, not otherwise specified (NOS) 16%, squamous cell 12%, and large cell 4%. Stage distribution was: 16% IB, 4% IIB, and 79% IIIA. Treatment was well tolerated and only one patient had a grade 4 toxicity. The median follow up was 95 months. The 5 year progression free survival (PFS) and overall survival (OS) for the entire population were 54 and 67%, respectively. Eighteen patients had a baseline FDG-PET scan and a repeat scan at day 18–21 available for comparison. Ten patients (56%) were considered metabolic responders on the day 18–21 FDG-PET scan. Responders had a 5 year PFS and OS of 60 and 70%, respectively, while the percentage for non-responders was 63 and 75% (p = 0.96 and 0.85). This phase II trial did not demonstrate that a PET scan after one cycle of chemotherapy can predict survival outcomes of patients with NSCLC treated with neoadjuvant chemotherapy. NCT00227539 registered September 28th, 2005.
- 1 May 2018
- Published by Elsevier in Journal of Thoracic Oncology
- Vol. 13 (5) , 649-659
Inflammatory Gene Polymorphisms in Lung Cancer Susceptibility
- 1 May 2018
- Published by Elsevier in Journal of Thoracic Oncology
- Vol. 13 (5) , 649-659
Inflammatory Gene Polymorphisms in Lung Cancer Susceptibility
- 20 May 2017
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 35 (15_suppl) , e17506
Prognostic significance of performance status in patients with head and neck squamous cell carcinomas (HNSCC) receiving immune checkpoint monoclonal antibodies (ICmAB) in a single institution.
E17506 Background: The anti-PD1/-PDL1 ICmABs can result in objective responses in some (13-20%) patients (pts) with HNSCC. We evaluated clinical factors that may predict oncologic outcomes. Methods: We identified pts who received an ICmAB at our institution and retrospectively collected demographic, tumor, treatment, progression, and survival data. The Kaplan Meier method was used to estimate survival. Log-rank and Wilcoxon tests were used to explore associations between clinical features and outcomes. Results: 55 pts received ICmAB in a clinical trial at our center from 8/2012 to 12/2016. The median age was 64 years, 13 (24%) were female, and 45 (82%) were white. ECOG Performance Status (PS) was 0 and 1 in 23 (42%) and 32 (58%) pts, respectively. 29 (53%) were current/former smokers who smoked a median of 20 (range 0-70) pack years. Primary sites included: oropharynx (OP) 31 (56%), oral cavity 9 (16%), nasopharynx 6 (11%), nasal cavity 3 (5%), hypopharynx (HP) 2 (4%), unknown (UK) 2 (4%), and skin 2 (4%). 28 (51%) were p16+, with the following primary sites: OP in 26, UK in 1, and HP in 1. 53 (96%) received prior curative intent therapy. A median of 2 (range 0-5) lines of systemic therapy (including curative intent) were given prior to ICmAB initiation, and 31 received an ICmAB as a single agent. There were 19 (35%) objective responses with 1 complete response, and 14 (25%) had stable disease. With a median follow-up of 12 months (m), the median overall survival (OS) was 15m (95% CI 11,47), and median time to progression was 4m (95% CI 2.2, 6.8). An ECOG PS of 0 vs 1 was associated with superior OS (36m vs 11m p = 0.001). Tobacco use, p16+ disease, single agent ICmAB vs. combination, number of lines of prior systemic therapy, or radiation therapy within 3m prior to ICmAB initiation did not appear to have a relationship with survival. Conclusions: A PS of 0 predicted for more favorable OS among HNSCC pts receiving ICmAB in this single center retrospective cohort. In contrast to data with chemotherapy, established prognostic markers (including p16+ and limited/no tobacco use) did not appear to impact survival.
- 20 May 2017
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 35 (15_suppl) , e17506
Prognostic significance of performance status in patients with head and neck squamous cell carcinomas (HNSCC) receiving immune checkpoint monoclonal antibodies (ICmAB) in a single institution.
E17506 Background: The anti-PD1/-PDL1 ICmABs can result in objective responses in some (13-20%) patients (pts) with HNSCC. We evaluated clinical factors that may predict oncologic outcomes. Methods: We identified pts who received an ICmAB at our institution and retrospectively collected demographic, tumor, treatment, progression, and survival data. The Kaplan Meier method was used to estimate survival. Log-rank and Wilcoxon tests were used to explore associations between clinical features and outcomes. Results: 55 pts received ICmAB in a clinical trial at our center from 8/2012 to 12/2016. The median age was 64 years, 13 (24%) were female, and 45 (82%) were white. ECOG Performance Status (PS) was 0 and 1 in 23 (42%) and 32 (58%) pts, respectively. 29 (53%) were current/former smokers who smoked a median of 20 (range 0-70) pack years. Primary sites included: oropharynx (OP) 31 (56%), oral cavity 9 (16%), nasopharynx 6 (11%), nasal cavity 3 (5%), hypopharynx (HP) 2 (4%), unknown (UK) 2 (4%), and skin 2 (4%). 28 (51%) were p16+, with the following primary sites: OP in 26, UK in 1, and HP in 1. 53 (96%) received prior curative intent therapy. A median of 2 (range 0-5) lines of systemic therapy (including curative intent) were given prior to ICmAB initiation, and 31 received an ICmAB as a single agent. There were 19 (35%) objective responses with 1 complete response, and 14 (25%) had stable disease. With a median follow-up of 12 months (m), the median overall survival (OS) was 15m (95% CI 11,47), and median time to progression was 4m (95% CI 2.2, 6.8). An ECOG PS of 0 vs 1 was associated with superior OS (36m vs 11m p = 0.001). Tobacco use, p16+ disease, single agent ICmAB vs. combination, number of lines of prior systemic therapy, or radiation therapy within 3m prior to ICmAB initiation did not appear to have a relationship with survival. Conclusions: A PS of 0 predicted for more favorable OS among HNSCC pts receiving ICmAB in this single center retrospective cohort. In contrast to data with chemotherapy, established prognostic markers (including p16+ and limited/no tobacco use) did not appear to impact survival.
- 20 May 2016
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 34 (15_suppl) , 6048
Racial disparity in oncologic and patient-reported quality of life (PROs) outcomes in patients with locally advanced head and neck squamous cell carcinomas (HNSCC) enrolled in a randomized phase II trial.
6048 Background: Using PROs from our previously completed clinical trial (NCT00410826), we conducted an exploratory analysis to identify PRO associations with clinical factors and oncologic outcomes. Methods: From 12/2006 to 10/2011, 204 patients(pts) were randomized to cisplatin 100mg/m2 on radiation (XRT) days(d)1, 22, and 43 concurrent with 70Gy XRT (Arm A) or the same treatment with erlotinib 150mg daily starting XRT d-7 until XRT completion (Arm B). Using the validated University of Washington QOL form, PROs were measured on XRT d-7 (Arm B only), d0, d30, and d180. PRO associations with clinical factors and oncologic outcomes were explored using linear mixed, logistic and cox models, while adjusting for potential confounders. Results: One hundred eighty nine (93%) [Arm A (N = 97); Arm B (N = 92)] pts consented to PRO collection. PRO scores were available in Arm A: 55 (56%) pts at d0, 65 (67%) at d30, and 45 (46%) at d180 and Arm B: 82 (89%) pts at d-7, 58 (63%) at d0, 69 (75%) at d30, and 41 (44%) at d180. Demographic and tumor characteristics were well-balanced apart from more females in Arm A [20 (19%) vs 8 (8%); p = 0.03]. There were 7 (16%) black pts in Arm A and 13 (13%) in Arm B (p = 0.28). There was no change in mean PRO scores from d-7 on d0 (p = 0.83). Scores were significantly lower in both arms at d30 (estimated difference from baseline -13.21 (CI -18.32, -8.1), with no significant difference by Arm (p = 0.71). D180 remained lower than d-7 for Arm A (estimated difference from baseline -6.56 (CI -12.30, -0.82) p = 0.03), however were not significantly different from d-7 (baseline) in Arm B (p = 0.68). After adjusting for potential confounders on multivariable analysis, black race was an independent predictor for inferior PRO scores [OR -15.87; 95% CI (-21.11, -10.63); p < 0.0001] at all timepoints, complete response rates [OR 0.23; 95% CI (0.1, 0.53); p < 0.001] and overall survival [OR 3.94; 95% CI (1.89, 8.24); p < 0.001]. Conclusions: PRO worsened during chemoradiation, but returned to baseline in pts on Arm B. Black pts had inferior PRO and overall survival, meriting further investigation.
- 20 May 2016
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 34 (15_suppl) , 6048
Racial disparity in oncologic and patient-reported quality of life (PROs) outcomes in patients with locally advanced head and neck squamous cell carcinomas (HNSCC) enrolled in a randomized phase II trial.
6048 Background: Using PROs from our previously completed clinical trial (NCT00410826), we conducted an exploratory analysis to identify PRO associations with clinical factors and oncologic outcomes. Methods: From 12/2006 to 10/2011, 204 patients(pts) were randomized to cisplatin 100mg/m2 on radiation (XRT) days(d)1, 22, and 43 concurrent with 70Gy XRT (Arm A) or the same treatment with erlotinib 150mg daily starting XRT d-7 until XRT completion (Arm B). Using the validated University of Washington QOL form, PROs were measured on XRT d-7 (Arm B only), d0, d30, and d180. PRO associations with clinical factors and oncologic outcomes were explored using linear mixed, logistic and cox models, while adjusting for potential confounders. Results: One hundred eighty nine (93%) [Arm A (N = 97); Arm B (N = 92)] pts consented to PRO collection. PRO scores were available in Arm A: 55 (56%) pts at d0, 65 (67%) at d30, and 45 (46%) at d180 and Arm B: 82 (89%) pts at d-7, 58 (63%) at d0, 69 (75%) at d30, and 41 (44%) at d180. Demographic and tumor characteristics were well-balanced apart from more females in Arm A [20 (19%) vs 8 (8%); p = 0.03]. There were 7 (16%) black pts in Arm A and 13 (13%) in Arm B (p = 0.28). There was no change in mean PRO scores from d-7 on d0 (p = 0.83). Scores were significantly lower in both arms at d30 (estimated difference from baseline -13.21 (CI -18.32, -8.1), with no significant difference by Arm (p = 0.71). D180 remained lower than d-7 for Arm A (estimated difference from baseline -6.56 (CI -12.30, -0.82) p = 0.03), however were not significantly different from d-7 (baseline) in Arm B (p = 0.68). After adjusting for potential confounders on multivariable analysis, black race was an independent predictor for inferior PRO scores [OR -15.87; 95% CI (-21.11, -10.63); p < 0.0001] at all timepoints, complete response rates [OR 0.23; 95% CI (0.1, 0.53); p < 0.001] and overall survival [OR 3.94; 95% CI (1.89, 8.24); p < 0.001]. Conclusions: PRO worsened during chemoradiation, but returned to baseline in pts on Arm B. Black pts had inferior PRO and overall survival, meriting further investigation.
- 20 May 2016
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 34 (15_suppl) , 6095
Phase II trial of eribulin for recurrent or metastatic salivary gland cancers.
6095 Background: Salivary gland cancers (SGC) are rare, biologically and histologically diverse malignancies with no standard of care therapy in the recurrent/metastatic setting. Eribulin is a microtubule inhibitor with established efficacy in previously treated breast cancer. The purpose of this study was to determine the anticancer activity of eribulin in advanced SGC. Methods: In a single center two-stage single arm phase II design, patients with progressive, recurrent and/or metastatic SCG of the head and neck or other sites, with documented disease progression within the past 6 months and not amenable to curative intent therapy were eligible. Any number of prior cytotoxic chemotherapies was allowed. Patients received eribulin 1.4 mg/m2 IV on Days 1 and 8 of a 21-day cycle until disease progression or unacceptable toxicities. Response was assessed by CT imaging every 6 weeks. The primary endpoint was overall response rate by RECIST 1.1. Secondary endpoints were duration of response (DOR), progression free survival (PFS), disease control rate (DCR), and grade > = 3 toxicities. Results: Between May 2012 and August 2015, 29 patients were enrolled. Median age was 63 (range 34-75); 20 (69%) were male. The most common histologies were adenoid cystic (n = 10) and adenocarcinoma (n = 5). Prior radiation was administered in 25 (86%). Number of prior cytotoxic therapies were: 0 (12, 41%), 1 (13, 45%), 3(3, 10%), 5 (1, 3%). Neutropenia was the most common toxicity (Grade 3 (9, 31%), Grade 4 (4, 14%)). Other grade 3 toxicities were: febrile neutropenia, increased QTc, fatigue and peripheral neuropathy in a single patient each. Median follow-up is 2 years, with 5 patients continuing on treatment. The median number of cycles administered was 4 (range 2-28). Response by RECIST criteria was observed in 3/29 (10%) with 2 PR and 1 CR , 20/29 (69%) patients demonstrated a decrement in tumor size at first assessment. Median PFS was 3 months, DCR was 26/29 (90%) and median DOR was 17.2 months. Conclusions: In this phase II trial of eribulin for advanced SGC, we observed response rates similar to those reported to other cytotoxic therapies and superior to those observed in trials of TKIs. Toxicities were similar to those observed in prior trials with eribulin. Clinical trial information: NCT01613768.
- 20 May 2016
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 34 (15_suppl) , 6095
Phase II trial of eribulin for recurrent or metastatic salivary gland cancers.
6095 Background: Salivary gland cancers (SGC) are rare, biologically and histologically diverse malignancies with no standard of care therapy in the recurrent/metastatic setting. Eribulin is a microtubule inhibitor with established efficacy in previously treated breast cancer. The purpose of this study was to determine the anticancer activity of eribulin in advanced SGC. Methods: In a single center two-stage single arm phase II design, patients with progressive, recurrent and/or metastatic SCG of the head and neck or other sites, with documented disease progression within the past 6 months and not amenable to curative intent therapy were eligible. Any number of prior cytotoxic chemotherapies was allowed. Patients received eribulin 1.4 mg/m2 IV on Days 1 and 8 of a 21-day cycle until disease progression or unacceptable toxicities. Response was assessed by CT imaging every 6 weeks. The primary endpoint was overall response rate by RECIST 1.1. Secondary endpoints were duration of response (DOR), progression free survival (PFS), disease control rate (DCR), and grade > = 3 toxicities. Results: Between May 2012 and August 2015, 29 patients were enrolled. Median age was 63 (range 34-75); 20 (69%) were male. The most common histologies were adenoid cystic (n = 10) and adenocarcinoma (n = 5). Prior radiation was administered in 25 (86%). Number of prior cytotoxic therapies were: 0 (12, 41%), 1 (13, 45%), 3(3, 10%), 5 (1, 3%). Neutropenia was the most common toxicity (Grade 3 (9, 31%), Grade 4 (4, 14%)). Other grade 3 toxicities were: febrile neutropenia, increased QTc, fatigue and peripheral neuropathy in a single patient each. Median follow-up is 2 years, with 5 patients continuing on treatment. The median number of cycles administered was 4 (range 2-28). Response by RECIST criteria was observed in 3/29 (10%) with 2 PR and 1 CR , 20/29 (69%) patients demonstrated a decrement in tumor size at first assessment. Median PFS was 3 months, DCR was 26/29 (90%) and median DOR was 17.2 months. Conclusions: In this phase II trial of eribulin for advanced SGC, we observed response rates similar to those reported to other cytotoxic therapies and superior to those observed in trials of TKIs. Toxicities were similar to those observed in prior trials with eribulin. Clinical trial information: NCT01613768.
- Open Access
- 3 October 2012
- Published by Springer Nature in BMC Cancer
- Vol. 12 (1) , 449
A Phase II study of pulse dose imatinib mesylate and weekly paclitaxel in patients aged 70 and over with advanced non-small cell lung cancer
In non-small cell lung cancer (NSCLC), interstitial hypertension is a barrier to chemotherapy delivery, and is mediated by platelet derived growth factor receptor (PDGFR). Antagonizing PDGFR with imatinib may improve intra-tumoral delivery of paclitaxel, increasing response rate (RR).
- 3 October 2012
- Published by Springer Nature in BMC Cancer
- Vol. 12 (1) , 449
Open AccessA Phase II study of pulse dose imatinib mesylate and weekly paclitaxel in patients aged 70 and over with advanced non-small cell lung cancer
In non-small cell lung cancer (NSCLC), interstitial hypertension is a barrier to chemotherapy delivery, and is mediated by platelet derived growth factor receptor (PDGFR). Antagonizing PDGFR with imatinib may improve intra-tumoral delivery of paclitaxel, increasing response rate (RR).
- Open Access
Estrogen Signaling in Lung Cancer: An Opportunity for Novel Therapy
Lung cancer is the leading cause of cancer death in U.S. and represents a major public health burden. Epidemiologic data have suggested that lung cancer in women may possess different biological characteristics compared to men, as evidenced by a higher proportion of never-smokers among women with lung cancer. Emerging data indicate that female hormones such as estrogen and progesterone play a significant role in lung carcinogenesis. It has been reported that estrogen and progesterone receptors are expressed in lung cancer cell lines as well as in patient-derived tumors. Hormone related risk factors such as hormone replacement therapy have been implicated in lung carcinogenesis and several preclinical studies show activity of anti-estrogen therapy in lung cancer. In this review, we summarize the emerging evidence for the role of reproductive hormones in lung cancer and implications for lung cancer therapy.
Open AccessEstrogen Signaling in Lung Cancer: An Opportunity for Novel Therapy
Lung cancer is the leading cause of cancer death in U.S. and represents a major public health burden. Epidemiologic data have suggested that lung cancer in women may possess different biological characteristics compared to men, as evidenced by a higher proportion of never-smokers among women with lung cancer. Emerging data indicate that female hormones such as estrogen and progesterone play a significant role in lung carcinogenesis. It has been reported that estrogen and progesterone receptors are expressed in lung cancer cell lines as well as in patient-derived tumors. Hormone related risk factors such as hormone replacement therapy have been implicated in lung carcinogenesis and several preclinical studies show activity of anti-estrogen therapy in lung cancer. In this review, we summarize the emerging evidence for the role of reproductive hormones in lung cancer and implications for lung cancer therapy.
- 1 August 2008
- Published by Springer Nature in Current Pain and Headache Reports
- Vol. 12 (4) , 270-276
Cancer pain: Perspectives of a medical oncologist
- 1 August 2008
- Published by Springer Nature in Current Pain and Headache Reports
- Vol. 12 (4) , 270-276
Cancer pain: Perspectives of a medical oncologist